Treatment of NSCLC has been significantly improved by the discovery of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; however, the effectiveness of these inhibitors is highly related to the EGFR genotype of the patient2. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.